Vergleich klinischer Parameter
| Parameter | Wert | MUC, muzinöses Karzinom |
MUMPC Muzinöses Karzinom mit mikropapillärer Komponente |
IMPC, Invasives mikropapilläres Karzinom |
IDMPC, invasives duktales Karzinom mit mikropapillärer Komponente |
Bemerkungen |
| Patientinnen | 19 | 17 | 15 | 13 | ||
| Alter | 52,7 ± 14,0 a | 53,9 ± 11,8 a | 45,9 ± 11,7 a | 54,3 ± 12,6 a | ||
| NG, nuklearer Grad | Low | 6 (31,6%) | 1 (5,9%) | 0 | 0 | IMPC häufiger hohe Kernmalignität p < 0,01 |
| Intermediate | 11 (57,9%) | 14 (82,4%) | 4 (26,7%) | 4 (30,8%) | ||
| High | 2 (10,5%) | 2 (11,8%) | 11 (73,3%) | 9 (69,2%) | ||
| Mitosen | Low | 16 (84,2%) | 13 (76,5%) | 2 (13,3%) | 2 (15,4%) | IMPC häufiger viele Mitose p < 0,01 |
| Intermediate | 1 (5,3%) | 4 (23,5%) | 3 (20,0%) | 3 (23,1%) | ||
| High | 2 (10,5%) | 0 | 10 (66,7%) | 8 (61,5%) | ||
| ER | Negativ | 0 | 0 | 5 (33,3%) | 4 (30,8%) | IMPC häufiger Rezeptor negativ p = 0,04 |
| Positiv | 19 (100%) | 17 (100%) | 10 (66,7%) | 9 (69,2%) | ||
| PR | Negativ | 1 (5,3%) | 1 (5,9%) | 7 (46,7%) | 5 (38,5%) | p = 0,04 |
| Positiv | 18 (94,7%) | 16 (94,1%) | 8 (53,3%) | 8 (61,5%) | ||
| HER2 | Negativ | 18 (94,7%) | 16 (94,1%) | 9 (60,0%) | 8 (61,5%) | IMPC häufiger Her2-positiv p = 0,01 |
| Positiv | 1 (5,3%) | 1 (5,9%) | 6 (40,0%) | 5 (38,5%) | ||
| Ki-67 | niedrig | 11 (57,9%) | 7 (41,2%) | 1 (6,7%) | 1 (7,7%) | IMPC häufiger hohe Mitoserate p < 0,01 |
| hoch | 8 (42,1%) | 10 (58,8%) | 14 (93,3%) | 12 (92,3%) | ||
| MS, molekularer Subtyp | LA | 11 (57,9%) | 6 (35,3%) | 1 (6,7%) | 1 (7,7%) | IMPC häufiger Her2- und Basal-Like-Subtyp p < 0,01 |
| LB | 8 (42,1%) | 11 (64,7%) | 9 (60,0%) | 8 (61,5%) | ||
| HER2 | 0 | 0 | 2 (13,3%) | 2 (15,4%) | ||
| Basal-like | 0 | 0 | 3 (20,0%) | 2 (15,4%) | ||
| T-Stadium | 1 | 11 (57,9%) | 6 (35,3%) | 6 (40,0%) | 4 (30,8%) | ns. |
| 2 | 7 (36,8%) | 7 (41,2%) | 6 (40,0%) | 7 (53,8%) | ||
| 3 | 1 (5,3%) | 4 (23,5%) | 3 (20,0%) | 2 (15,4%) | ||
| LNM, Lymphknoten - Metastasierung | N+ | 17 (89,5%) | 13 (76,5%) | 3 (20,0%) | 4 (30,8%) | IMPC häufiger positive Lymphknoten p < 0,01 |
| N- | 2 (10,5%) | 4 (23,5%) | 12 (80,0%) | 9 (69,2%) | ||
Nach Zahlen von (1)
Teil von
Prognostic Significance of a Micropapillary Pattern in Pure Mucinous Carcinoma of the Breast: Comparative Analysis with Micropapillary Carcinoma.
Journal of Pathology and Translational Medicine 2017; 51: 403-409
https://doi.org/10.4132/jptm.2017.03.18
2.) Siriaunkgul S, Tavassoli FA:
Invasive micropapillary carcinoma of the breast.
Mod Pathol 1993; 6: 660–2.
3.) Zekioglu O, Erhan Y, Ciris M, Bayramoglu H, Ozdemir N:
Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma.
Histopathology 2004; 44: 18–23.
